When Does Japan’s Advanced Medical Care B Make Sense for Medical Device Companies?

An opportunity to enable clinical use before reimbursement and build relationships with Japanese healthcare institutions

Why Should Medical Device Companies Pay Attention?

Japan’s Advanced Medical Care B system (先進医療B) can offer a route for selected medical technologies to be used in clinical practice at designated Japanese medical institutions before they become eligible for reimbursement under Japan’s National Health Insurance (NHI) system.

For international medical device companies, this may create several potential advantages:

  • Earlier clinical use: The opportunity for selected patients to receive a technology in a designated medical institution before it is covered by NHI.
  • Experience in Japanese clinical practice: Physicians and hospitals can gain experience using the technology in a defined clinical setting.
  • Physician engagement: The framework can help establish relationships with Japanese specialists and potential clinical champions.
  • Clinical and commercial preparation: Companies can better understand how a technology fits into Japanese clinical workflows and what may be required for broader adoption.
  • Potential progress toward reimbursement: The evaluation process can support consideration of whether the technology should ultimately be included in the NHI system.

However, Advanced Medical Care B is not a general market-entry route, a substitute for medical device approval, or a guaranteed source of pre-approval revenue. Its potential value depends on the technology, the clinical need, the participating institution and the company’s broader Japan strategy.

How Does the Application Process Work?

One important point for overseas manufacturers to understand is that a medical device company cannot apply directly for Advanced Medical Care B designation.

The application must be made by a qualifying medical institution to Japan’s Ministry of Health, Labour and Welfare (MHLW). The institution must meet the applicable facility requirements for the specific technology and its proposed clinical application.

Designation is therefore specific to both the medical institution and the technology. It is not a general designation granted to a manufacturer’s product that can then be used at any hospital.

Applications undergo expert-panel review, and the process typically takes approximately six months, although the actual timeline can vary depending on the application and review process.

For manufacturers, this means that identifying and working with an appropriate Japanese hospital and clinical investigator is an essential first step. The company may provide technical information, clinical evidence and other support, but the medical institution is the applicant and must take responsibility for meeting the relevant requirements.

What Types of Medical Devices Might Be Relevant?

Advanced Medical Care B can apply to medical technologies involving unapproved medical devices or approved devices used outside their approved indications or conditions of use, where the proposed technology requires focused evaluation of safety and effectiveness.

Potentially relevant examples may include:

  • Innovative interventional devices and procedures.
  • New surgical and robotic technologies.
  • Advanced imaging and diagnostic technologies.
  • Novel implants and other therapeutic devices.
  • New clinical applications or indications for existing devices.
  • Technologies with promising overseas experience but limited evidence or clinical experience in Japan.

These are illustrative categories, not a list of automatically eligible products. Eligibility is assessed in relation to the specific technology, clinical application, supporting evidence, proposed protocol and capabilities of the medical institution.

The distinction is important: the framework applies to a defined medical technology and its use at a designated institution, not simply to a manufacturer’s product as a whole.

When Should a Company Explore Advanced Medical Care B?

For an international medical device company, there are several situations where investigating this framework may be worthwhile.

1. There is a need for clinical use before NHI reimbursement

A technology may have a clear clinical rationale but not yet have an established reimbursement route in Japan. Advanced Medical Care B may provide an opportunity for its use in a defined clinical setting, with the advanced medical treatment component generally paid for by the patient.

This can be particularly relevant where there is a strong clinical need and a specialist physician prepared to introduce the technology.

2. Japanese clinical experience would help establish adoption

Some medical technologies require more than regulatory clearance to gain acceptance. Physicians need to understand how a device performs in practice, how it fits into existing procedures and workflows, and what benefits it offers compared with current treatment options.

Advanced Medical Care B may provide a structured opportunity for participating physicians and institutions to gain this experience.

This is clinical care under an evaluation framework, not a conventional GCP clinical trial. Companies should understand the distinction when considering the type of evidence generated and its potential uses.

3. There is a strong Japanese clinical champion

A committed physician or medical institution is often central to the feasibility of this approach.

The technology must address a meaningful clinical need, and the institution must be willing and able to take responsibility for the application, meet the facility requirements and conduct the proposed treatment and evaluation.

Without an appropriate institutional partner, the manufacturer cannot independently move the process forward.

4. There is a credible opportunity to progress toward reimbursement

The framework may be worth investigating where there is a realistic prospect that the technology could eventually be considered for NHI coverage.

Companies should assess the potential patient population, clinical value, competing treatments, likely patient out-of-pocket costs and the commercial implications of future reimbursement.

First Understand the Conventional Japanese Approval Pathway

Before considering Advanced Medical Care B, manufacturers should establish what is actually required to make their device available in Japan.

Japan does accept appropriate foreign clinical data in medical device applications. A Japanese clinical study is not automatically required simply because a product is being introduced into the Japanese market.

The regulatory route depends on the device’s classification and whether applicable Japanese certification standards exist.

In simplified terms:

  • Notification (届出): Generally applies to Class I medical devices.
  • Third-party certification (認証): Applies to Class II and certain Class III devices where an applicable certification standard exists.
  • Marketing approval (承認): Required for devices outside the notification and certification routes, including Class IV devices. These applications are reviewed by PMDA.

The appropriate first step is a regulatory gap assessment and, where appropriate, consultation with PMDA. This helps determine whether existing overseas evidence is sufficient, whether additional Japanese data may be needed, and what development or regulatory work remains.

Advanced Medical Care B should be considered separately from this approval assessment. It is not a shortcut through the PMDA review process.

What Is the Potential Business Value?

The potential value of Advanced Medical Care B is primarily related to clinical use, institutional experience and the evaluation of a technology for possible future NHI reimbursement.

For a company with an appropriate technology and hospital partner, it may offer:

Earlier clinical use before reimbursement

Selected patients may be able to receive the technology at a designated institution before the advanced medical treatment becomes covered by NHI.

Physician and institutional experience

Participating physicians can gain practical experience with the technology, potentially helping establish clinical familiarity and support future adoption.

Information for reimbursement evaluation

The framework involves evaluation and reporting of clinical outcomes. This information is relevant to the assessment of the technology for potential future inclusion in the NHI system.

Preparation for broader adoption

Working with a Japanese institution can help a company better understand local clinical practice, physician expectations, patient considerations and the operational requirements for wider use.

An important financial distinction is that the advanced medical treatment component is generally paid for by the patient, while eligible conventional medical services can continue to be covered by NHI. This does not mean that the device company can freely sell or distribute an unapproved product commercially, nor does it guarantee meaningful pre-reimbursement revenue.

Does Advanced Medical Care B Replace a PMDA Clinical Trial?

No. Companies should not view Advanced Medical Care B as a way to avoid a clinical trial that PMDA may require for marketing approval.

The primary purpose of the Advanced Medical Care framework is to evaluate a medical technology in the context of potential future NHI coverage. The resulting clinical information is generated within that framework and is principally relevant to the insurance evaluation process.

This is separate from the regulatory evidence requirements for obtaining marketing approval from PMDA. Although information generated through clinical use may be of interest in subsequent regulatory discussions, its relevance or acceptability for a separate approval application should not be assumed.

Companies should also distinguish Advanced Medical Care B from Japan’s conditional early approval system for certain innovative medical devices. Under qualifying circumstances, including serious unmet medical need and difficulty conducting conventional confirmatory studies, this separate system may allow approval based on limited clinical data together with post-marketing risk management and data collection.

Advanced Medical Care B does not automatically lead to conditional approval, replace PMDA requirements or guarantee that data collected through the framework will satisfy a marketing approval application.

When Might Advanced Medical Care B Not Make Sense?

Despite its potential advantages, the framework will not be appropriate for every medical device.

It may not be worthwhile where:

  • Existing overseas clinical data are likely to be sufficient for Japanese marketing approval.
  • PMDA requires only a relatively small or focused Japanese clinical study.
  • The device can follow a straightforward third-party certification route.
  • There is no suitable Japanese hospital or clinical investigator willing to lead an application.
  • The eligible patient population is too small to justify the effort and cost.
  • Patient out-of-pocket costs or the lack of reimbursement would limit practical adoption.
  • The time and resources required to obtain designation and conduct the evaluation outweigh the potential commercial or clinical benefits.

In some cases, pursuing conventional regulatory approval and reimbursement planning directly may be the more practical route.

What Should Companies Investigate Before Proceeding?

Before investing resources, manufacturers should consider five questions:

  1. Regulatory requirements: What is the applicable Japanese device classification and approval or certification route? Is a Japanese clinical study actually required?
  2. Clinical and reimbursement opportunity: Is there a meaningful clinical need, and is there a realistic prospect of future NHI coverage?
  3. Institutional partner: Is there a Japanese hospital and clinical investigator willing and able to lead the application and meet the facility requirements?
  4. Patient and commercial feasibility: Is the potential patient population sufficient, and would patient out-of-pocket costs allow meaningful use?
  5. Time and resources: Can the company support the institutional application, technical requirements, supply arrangements and evaluation process over the necessary period?

Companies should also clarify responsibilities with the participating institution, including device supply, technical support, data access, publication rights and the handling of any information generated.

Conclusion

Japan’s Advanced Medical Care B system can be worth exploring for selected medical device technologies, particularly where there is a meaningful clinical need, a committed Japanese medical institution and a credible opportunity to progress toward future NHI reimbursement.

However, it is important to understand what the framework does—and what it does not do. It is an institution-led route for defined clinical use and evaluation before reimbursement, not a manufacturer-led application, a substitute for PMDA approval or a guaranteed route to commercial sales.

For international manufacturers, the most sensible starting point is to assess the conventional Japanese regulatory pathway first, then determine whether Advanced Medical Care B offers a meaningful additional opportunity for clinical use and reimbursement evaluation.

Invision Japan supports international medtech companies in assessing Japan market opportunities, understanding regulatory and clinical development considerations, identifying Japanese clinical and commercial partners, and developing practical market-entry strategies. We help companies determine which opportunities are worth investigating before committing significant development resources.


Resources

Ministry of Health, Labour and Welfare (MHLW)

Pharmaceuticals and Medical Devices Agency (PMDA)

Common Issues with Distributors & Partners

🔹 Sales & Market Development Issues

  • Sales are stagnant or declining despite a growing market.
  • Distributor is reactive — they only process orders but don’t grow the business.
  • No new customer acquisition strategy or market development plan.
  • Poor understanding of competitive landscape and positioning.
  • Distributor is passive in lead generation or brand awareness.
  • They rely on inbound demand — no outbound activity or selling effort.
  • Sales staff seem poorly trained on the product or lack confidence.
  • Little or no presence at relevant industry events, conferences, or exhibitions.
  • Distributor is focused on easier products in their portfolio, not yours.
  • Sales targets are missed consistently, without serious attempts to recover.
  • They are not pushing key accounts or KOL engagement.

🔹 Marketing & Communication Failures

  • No local marketing strategy — just translation of global materials.
  • No digital presence or weak online visibility in Japanese.
  • Collateral is outdated, off-brand, or technically incorrect.
  • They don’t localize messaging — marketing doesn’t resonate with Japanese buyers.
  • Lack of alignment between marketing and sales functions.
  • No product launch campaigns — new offerings quietly added to catalog.
  • No proactive communication with HQ marketing or sales teams.
  • Weak communication cadence — months go by without updates.
  • No explanation for performance variances — just excuses or silence.

🔹 Transparency & Data Sharing Issues

  • Refusal to share end-customer lists or sales pipeline data.
  • No CRM or visibility into sales funnel.
  • Sales reports are vague, late, or manipulated.
  • KPIs are agreed upon but not tracked or enforced.
  • No clarity on pricing strategy, discounting, or margins.
  • They don’t share information about competitor activity.
  • Regulatory progress (or delays) is unclear or unverifiable.
  • Limited or no visibility into inventory, returns, or backorders.
  • They do not allow direct contact with key customers or users.
  • Concerns that they are misrepresenting your product in the field.

🔹 Strategic Misalignment

  • Distributor focuses on volume, while your product requires value selling.
  • They treat your product as secondary to others in their portfolio.
  • Incentive structures are misaligned with your growth goals.
  • They are not willing to co-invest in marketing or sales enablement.
  • Unclear or inconsistent positioning of your product in the market.
  • They decline to register new indications or versions of your product.
  • They block channel expansion or partnerships that could increase reach.
  • No interest in evolving to a more strategic partner role.

🔹 Legal & Structural Concerns

  • They own the local registration, blocking alternatives.
  • They refuse to transfer or share regulatory files or market authorization.
  • They claim exclusive rights but don’t deliver exclusive-level performance.
  • They insist on long contract renewals with no performance safeguards.
  • They resist performance clauses, audits, or visibility rights.
  • Concerns they may be working with your competitor under a different brand.

🔹 Cultural & Operational Disconnects

  • Avoidance of confrontation — problems are hidden until too late.
  • They say “yes” to your face, but do something else later.
  • Resistance to change — even small adjustments are “not possible.”
  • No escalation process — decisions take too long to travel up hierarchy.
  • Internal bureaucracy stifles responsiveness to customers or HQ.
  • Reluctance to adopt Western systems like CRM, KPIs, or shared dashboards.
  • They filter all communication — blocking or distorting messages from the field.
  • Face-saving prevents them from admitting lack of knowledge or capability.

🔹 Support & Training Gaps

  • Distributor staff lack technical knowledge of your product.
  • No structured onboarding for new sales reps or support staff.
  • They don’t offer field support during installations or launches.
  • Customers complain about slow or poor post-sale support.
  • No investment in technical certifications or continued learning.
  • Distributor uses third parties without informing you (sub-agents, dealers, etc.)

🔹 Commercial Misalignment

  • They demand deep discounts or rebates without clear ROI.
  • They shift commercial risk back to you — refusing inventory or slow payers.
  • Price erosion due to poor positioning or channel management.
  • Focus on protecting margins instead of growing market share.
  • They underprice your product to move stock — harming brand perception.

Success in Japan Starts with Owning the Customer: The Case for Direct Entry

Japan is often approached as a “partner market.” Find a distributor, sign a deal, and let them handle commercialization.

That model can work but it comes with a fundamental trade-off: you give up the customer.

For companies with strong assets and long-term ambition, there is a different path—one that is increasingly viable in Japan today: building your own local presence and engaging the market directly.


The Strategic Advantage: Owning the Customer Relationship

In Japan, relationships are not transactional—they are built over time, grounded in trust, consistency, and local relevance.

When you operate through a third party, you are one step removed from:

  • Physicians and KOLs
  • Hospital systems
  • Payers and policy influencers
  • Real-world patient experience

That distance matters.

Without direct engagement, you miss:

  • Unfiltered market feedback on your product’s positioning and usage
  • Early signals on competitive threats or shifting treatment patterns
  • The ability to adapt your strategy in real time

Over time, this creates a structural disadvantage. You are not truly in the market—you are observing it through someone else’s lens.


From Product Revenue to Market Equity

A distributor can generate sales.

A subsidiary builds equity.

When you establish your own presence in Japan, you are not just commercializing a product—you are building:

  • A recognized brand among healthcare professionals
  • Direct credibility with regulators and payers
  • A platform for future launches
  • Institutional knowledge that compounds over time

This is particularly important in Japan, where continuity and reputation carry significant weight. The value of these assets often exceeds the near-term efficiency gained through outsourcing.


Control Drives Better Decisions

Operating directly gives you control over:

  • Positioning and messaging in a highly nuanced market
  • Pricing and market access strategy
  • Medical engagement and evidence generation
  • Lifecycle management and indication expansion

In a market with regular price revisions and evolving reimbursement dynamics, this control is not just beneficial—it is critical.


“Japan Is Too Difficult” — Less True Than It Used to Be

Historically, companies avoided direct entry due to perceived barriers:

  • Talent constraints
  • Regulatory complexity
  • Cultural and language differences

These challenges still exist—but they are increasingly manageable:

  • Japan is more open to foreign companies than ever before
  • Experienced local talent is available, particularly for compelling products
  • Regulatory pathways are more transparent with early engagement

In reality, many of the risks associated with building a subsidiary are execution challenges not structural barriers.


When a Direct Model Makes Sense

Building your own subsidiary is not for every company. It becomes compelling when:

  • You have a differentiated or high-value asset
  • Japan is a strategic, not opportunistic, market
  • You are willing to invest with a multi-year horizon
  • Customer insight and lifecycle control are critical to success

In these situations, the question is not “Can we afford to build?”
It is often “Can we afford not to?”


A More Flexible Reality: Start Direct, Scale Smart

Direct entry does not mean building everything at once.

Many successful companies:

  • Establish a small, focused local team
  • Hold key functions (strategy, KOL engagement, market access) internally
  • Selectively outsource execution where needed

This approach allows you to own the customer relationship from day one, while scaling infrastructure over time.


The Bottom Line

Japan rewards companies that commit.

If you rely entirely on partners, you may gain speed—but you limit your visibility, control, and long-term upside.

If you build your own presence, you gain something far more valuable:

  • Direct insight
  • Strategic control
  • Enduring market equity

In a market like Japan, those advantages compound and ultimately define who wins.

Why Companies Should Seriously Consider Selling in Japan

For companies seeking sustainable growth, Japan represents one of the most attractive, stable, and integrity-driven markets in the world. Despite its reputation for being selective and culturally complex, Japan consistently rewards those who approach it strategically—with high customer loyalty, predictable profitability, and long-term brand value.

Below are key reasons why entering Japan should be part of every company’s international growth strategy.


1. A High-Value Market That Rewards Quality

Japan is the third-largest economy globally, with consumer spending power that rivals the United States and Europe. But what makes Japan truly distinctive is not its size—it’s the depth and durability of its demand.
Japanese consumers value performance, craftsmanship, and service. Products that meet these expectations often enjoy premium pricing and remarkable brand longevity..


2. Business Culture Built on Trust and Integrity

Japan’s commercial environment is one of the most transparent and ethical in the world. Contracts are respected, invoices are paid on time, and business relationships are built on mutual trust rather than short-term opportunism.
For global executives used to managing risk in volatile or opaque markets, Japan offers a predictable, rules-based ecosystem where ethical business still holds real competitive advantage.


3. Long-Term Partnerships Over Quick Transactions

Japanese distributors and corporate clients rarely switch suppliers without cause. Once trust is established, relationships tend to be long-lasting and mutually beneficial.
This stability reduces churn, lowers business development costs over time, and allows companies to build steady recurring revenue from a mature and loyal customer base.


4. Strategic Gateway to Asia

A successful presence in Japan often becomes a springboard into broader Asia-Pacific expansion. Japanese partners, investors, and distributors carry global credibility, and a product that succeeds in Japan gains reputational leverage across Asia.
Many companies have found that “validated in Japan” opens doors not only in Korea, Taiwan, and Singapore, but even in Western markets where Japanese endorsement signals reliability and quality.


5. Exceptional Infrastructure and Supply Chain Reliability

Japan’s infrastructure—from logistics to data networks—is world-class. Distribution networks operate with near-perfect reliability, and the country’s advanced e-commerce, healthcare, and manufacturing ecosystems make it an ideal environment for precision-driven products and services.
For companies concerned with supply chain disruption or counterfeit risk, Japan offers a secure, transparent, and well-regulated platform for commercial operations.


6. A Market That Strengthens Your Global Brand

Doing well in Japan is more than a commercial success—it’s a statement of capability. Japanese consumers and corporate buyers are among the world’s most discerning. If your product meets their expectations, it can meet anyone’s.
Global companies often find that success in Japan enhances brand reputation, investor confidence, and competitive positioning worldwide.


7. Strong Legal and IP Protection Framework

Japan’s intellectual property laws and enforcement mechanisms rank among the most robust globally. For companies in pharmaceuticals, medtech, software, and design, this makes Japan a safe market for technology transfer, innovation partnerships, and high-value intellectual assets.


Final Word: Japan Rewards Serious, Strategic Entrants

Japan is not a market for opportunistic or short-term players. It demands commitment, quality, and cultural understanding. But for companies that invest properly, Japan delivers steady profits, low business risk, and unmatched reputational value.

At Invision Japan, we specialize in helping companies enter, manage, and grow their business in Japan—bridging the cultural gap and aligning local partners for long-term success.

Distributor Due Diligence in Life Sciences: Tips, Tricks, and Fixes for Existing Partnerships

Choosing the right distributor is one of the most critical decisions for life sciences companies entering or expanding in a new market. Whether in pharmaceuticals, biopharmaceuticals, medical devices, or med-tech, the wrong partner can slow growth, damage your brand, or block market access entirely.

This guide offers practical tips for carrying out thorough due diligence when selecting a new distributor, as well as strategies for correcting course in existing partnerships when the initial diligence didn’t reveal key issues.


Part 1: Operational & Commercial Due Diligence for New Distributors

Effective due diligence goes far beyond reviewing financial statements. Assessing whether a distributor can actually sell your product requires a deep dive into operational, commercial, and strategic capabilities.

1. Sales Force Structure and Coverage

  • Number of reps covering your product category.
  • Geographic reach and account segmentation.
  • Experience with similar products or therapeutic areas.

2. Track Record of Product Launches

  • Historical success launching similar products.
  • Time-to-market performance for previous launches.
  • Ability to meet sales targets consistently.

3. Customer Access and Relationships

  • Depth and quality of relationships with hospitals, clinics, labs, or pharmacies.
  • Access to KOLs and decision-makers.
  • Ability to navigate procurement or hospital approval processes.

4. Sales Processes and Metrics

  • Pipeline management and CRM usage.
  • Lead follow-up speed and frequency.
  • Reporting cadence, accuracy, and transparency.

5. Marketing and Promotion Capabilities

  • Preparedness to run product demos, webinars, or scientific events.
  • Existing marketing collateral and ability to adapt it for your product.
  • Budget allocation for promotional campaigns.

6. Team Expertise and Commitment

  • Knowledge of your product’s therapeutic area.
  • Training programs for sales reps.
  • Incentive structures aligned with your growth objectives.

7. Operational Risk Assessment

  • Ability to handle regulatory reporting, cold chain logistics (if applicable), and customer service.
  • Past incidents of compliance failures, stock-outs, or logistical delays.

Tip: Conduct site visits and ride-alongs if possible. Observing the team in action often reveals insights that documents or interviews cannot.


Part 2: Fixing Existing Partnerships When Due Diligence Was Missed or Misleading

Even the most thorough diligence cannot guarantee perfect results. When actual performance falls short, companies can take several steps:

1. Audit and Assess Current Performance

  • Conduct a competency audit: sales, marketing, reporting, regulatory compliance.
  • Compare actual results with initial expectations and contractual KPIs.

2. Improve Visibility and Transparency

  • Require more frequent and structured reporting.
  • Request access to customer or sales data (where possible).
  • Introduce dashboard tracking of key metrics.

3. Reset Expectations and Roles

  • Define clear KPIs and responsibilities moving forward.
  • Conduct workshops or training to align the distributor with your product strategy.

4. Provide Support

  • Offer marketing, sales, or clinical support to help them succeed.
  • Facilitate introductions to KOLs or hospital networks.

5. Plan for Exit or Transition if Needed

  • Maintain the ability to replace or supplement the distributor if performance doesn’t improve.
  • Include contingency clauses in agreements for future transitions.

Key Insight: It is much easier and cheaper to prevent issues upfront than to correct them later, but structured audits and incremental intervention can salvage underperforming relationships.


Key Takeaways

  • Due diligence is multi-dimensional: Commercial, regulatory, financial, strategic, and operational aspects all matter.
  • Standardized scoring systems help compare potential distributors objectively.
  • Missed diligence isn’t a lost cause: Audit, support, reset expectations, and maintain exit options.
  • Long-term foresight is critical: Changing distributors later is expensive and disruptive — plan and structure your agreements accordingly.

At Invision Japan, we help life sciences companies thoroughly vet new distributors and rescue underperforming partnerships in Japan. Whether you’re entering the market or correcting course, structured assessment and proactive management are the keys to sustained success.

Why Good Products Fail in Japan: It’s Not Always the Market

Many global executives are told the same story when sales in Japan disappoint:
“Japan is a difficult market.”
“Customers here are conservative.”
“The regulations are too strict.”

While there is truth in each of these statements, they are often used as a shield. In reality, many good products fail in Japan not because of the market itself, but because of issues closer to home: the structure, incentives, and performance of the chosen distributor or partner.


The Market Isn’t Always the Problem

Japan is the world’s third-largest economy. Customers here buy new medical devices, pharmaceuticals, technologies, and industrial products every day. Competitors launch and succeed. If your product has proven demand elsewhere, it’s unlikely that Japan is uniquely resistant.

What’s far more common is:

  • Distributor passivity – waiting for orders instead of creating demand.
  • Overreliance on existing relationships – your partner only pushes products that already sell.
  • Limited transparency – poor reporting hides weak performance until it’s too late.
  • Excuse-driven culture – “the market isn’t ready” becomes the default explanation for inaction.

Common Failure Patterns

  1. Early enthusiasm, fast fade.
    A Japanese distributor initially invests in the relationship, then quietly shifts focus back to their core products once the “newness” wears off.
  2. Big name, little effort.
    Companies often feel secure signing with a well-known trading house or distributor. But size doesn’t guarantee commitment — your product may never be more than a line item in a catalog.
  3. Blaming culture instead of strategy.
    Politeness masks underperformance. You hear reassurance in meetings, but no sales momentum in the field.

What This Means for You

If your product is struggling in Japan, don’t assume the market is the problem. Instead, ask:

  • Is our distributor really investing in this product, or just holding the license?
  • Are they providing real sales and market feedback, or just excuses?
  • Do we have visibility into their pipeline, customer meetings, and promotional activity?
  • Have we defined performance expectations — and what happens if they’re not met?

Fixing the Problem

Improving distributor performance in Japan isn’t easy — but it is possible. Options include:

  • Resetting the relationship – with clearer expectations, KPIs, and accountability.
  • Providing tools and support – sales training, marketing materials, or market data.
  • Applying pressure – making it clear that underperformance will lead to change.
  • Exploring alternatives – sometimes the right answer is to replace, not repair.

Final Thought

Good products fail in Japan not because of some mysterious barrier in the market, but because of misaligned partnerships, lack of transparency, and unaddressed distributor underperformance.

The market is there. The demand is there. The question is whether your partner is really opening the door — or standing in the way.


At Invision, we specialize in helping companies diagnose and fix partner challenges in Japan. If your product isn’t performing, it may not be the market — it may be your partner. And that can be fixed.

Why Japanese Distributors Can Be Your Best Ally – If You Manage the Relationship Well

When a company considers entering Japan, one of the first strategic choices is whether to establish a local office or work through a Japanese distributor. While both options have merit, the right distributor can be a remarkably effective way to launch, grow, and sustain your business in this unique market.

And yes—there are common stereotypes about Japanese distributors. Many of them are rooted in truth, and in the right context, they can be powerful advantages.


Positive Stereotypes (That Often Work in Your Favor)

  1. Long-Standing Relationships
    Many Japanese distributors have cultivated deep ties with customers, partners, and regulators over decades. That “relationship capital” can open doors that would take years to access on your own.
  2. Meticulous Quality and Attention to Detail
    From packaging to logistics to after-sales service, Japanese distributors often hold themselves to exacting standards that protect your brand’s reputation.
  3. Reliability and Consistency
    Commitments are taken seriously—deadlines are met, rules are followed, and promises are kept. That consistency can dramatically reduce operational headaches.
  4. Market Knowledge and Cultural Insight
    A seasoned distributor doesn’t just know the customer list—they understand how decisions are made, what customers value, and how to navigate competitive landscapes.
  5. Administrative and Regulatory Expertise
    Japan’s import rules, product certifications, and tax systems can be complex. Many distributors manage these processes in-house, sparing you the learning curve and overhead of doing it yourself.

Benefits of using a Distributor

Whether you sell consumer goods, industrial equipment, technology, or healthcare products, a strong Japanese distributor can:

  • Accelerate uptake by tapping into established networks
  • Minimize fixed costs by avoiding the expense of building a subsidiary
  • Reduce cultural and operational risk by letting a local partner handle sensitive relationship management

But—No “Set and Forget”

Even the most capable distributor needs active engagement to stay aligned with your goals. Risks include:

  • Over-cautious sales approaches that slow market penetration
  • Focus on familiar segments at the expense of new opportunities
  • Limited transparency on pricing, market data, or customer feedback

Without regular, structured communication, momentum can fade.


The Key: Active, Ongoing Partnership

The best results come when companies treat their distributor as a strategic partner, not just a vendor. That means:

  • Setting clear expectations and KPIs from day one
  • Scheduling regular visits and performance reviews
  • Sharing marketing, product, and training resources
  • Maintaining open, two-way communication

Bottom line: A Japanese distributor can be one of your most valuable growth partners—if you choose carefully and manage the relationship proactively. Done right, it gets you to market faster, protects your brand, and saves you from the complexity of going it alone.

If you need help finding, evaluating, or managing a Japanese distributor in any industry, InvisionJapan.com brings decades of hands-on experience to ensure your partnership delivers results.